Closing Session

Thursday, 10 October | 13:00 – 13:50

José Esparza

CS.01 | 13:00 – 13:20
What Has 30 Years of HIV Vaccine Research Taught Us? Lessons from The Past To Inform The Future

Bill & Melinda Gates Foundation, Seattle, WA, USA


Since 2004 José Esparza has been with the Bill & Melinda Gates Foundation in Seattle, WA first as Senior Advisor on HIV Vaccines and currently as Senior Advisor on Global Health (Vaccines.)

Previously in 1986, he joined the World Health Organization (WHO) in Geneva, Switzerland, to work on viral diseases with epidemic potential. When WHO launched its Global Program on AIDS (GPA) in 1987, Esparza established and led its Biomedical Research Unit. Later he became the Chief of the WHO/GPA Vaccine Development Unit. In 1996 he transitioned to the newly established United Nations Program on HIV/AIDS –UNAIDS (Geneva, Switzerland) as Coordinator of the WHO-UNAIDS HIV Vaccine Initiative.

From 1974 to 1985 he worked in Caracas, Venezuela, at the Venezuelan Institute of Scientific Research – IVIC. He served as Professor of Virology, Head of the Laboratory of Biology of Viruses and Chairman of the Center of Microbiology and Cell Biology. During this time he published extensively on rotaviruses associated with gastroenteritis. He is the author of over 175 papers on different aspects of virology, HIV/AIDS and vaccine development. Esparza has served in numerous national and international scientific advisory committees and boards, and until 2012 served as the interim President of the Board of the Global HIV Vaccine Enterprise. He is a member of the National Academy of Medicine of Venezuela and of the Royal Academy of Doctors of Spain.

He received his MD degree in his native country of Venezuela (1968) and a PhD in Virology and Cell Biology from Baylor College of Medicine in Houston, TX (1974).



CS.02 | 13:20 – 13:25
AIDS Vaccine 2013 At-A-Glance
2013 Conference Chairs

Christian Brander, Bonaventura Clotet, José M. Gatell


Nina Russell

CS.03 | 13:25 - 13:36
AIDS Vaccine Research, Where We Are and Where We Are Going

Nina Russell
Bill & Melinda Gates Foundation, Seattle, WA, USA;
Global HIV Vaccine Enterprise, New York, NY, USA


Nina Russell joined the Bill & Melinda Gates Foundation in 2005 as a Senior Program Officer in the HIV, TB and Reproductive Health Program where she focuses on the Foundations efforts related to HIV vaccines. She completed her residency in Internal Medicine at the New York Hospital-Cornell Medical Center and a clinical and research fellowship in Infectious Diseases at the Montefiore Medical Center – Albert Einstein College of Medicine after receiving an M.D. from Case Western Reserve University School of Medicine.

Prior to joining the Foundation, Dr. Russell held positions at the Fred Hutchinson Cancer Research Center and the University of Washington where she worked for six years on clinical HIV vaccine trials as part of the HIV Vaccine Trials Network (HVTN). She served as the Scientific Liaison in the Central Immunology Laboratory of the HVTN where she focused on the development and validation of immunological assays for vaccine trials. She later served in the HVTN Core Operations Center as a Senior Clinical Trials Physician where she managed the HVTN's pipeline of Phase I and II HIV vaccine clinical trials as the Lead for Protocol Development and Implementation.

Dr. Russell received the HVTN Network Service Award in May 2005, as well as a Certificate of Recognition of service from the NIAID, Division of AIDS. She currently serves on the NIH AIDS Vaccine Working Group and is board certified in Internal Medicine and Infectious Diseases.


CS.04 | 13:35 – 13:50
HIV Research for Prevention

2014 Conference Co-Chairs


Eric Hunter

Eric Hunter
Emory University, USA


Dr. Hunter's career has included undergraduate studies in bacteriology at Birmingham University, England, and graduate work in tumor immunology carried out at the Imperial Cancer Research Fund & Brunel University, London, England. During postdoctoral studies at the University of Southern California and following his move to UAB, he pioneered molecular genetics approaches to examine retrovirus replication.

His laboratory has been recognized internationally for its work in defining the molecular events involved in retroviral assembly and for elucidating the structure/function relationships for retroviral gene products at a molecular level. For the past several years his laboratory has investigated the molecular biological mechanisms underlying HIV transmission among heterosexual couples living in Rwanda and Zambia, as well as studies of how the host's immune system drives evolution of HIV, with an aim toward developing novel vaccine approaches that might prevent this transmission event. His bibliography includes over 200 articles, reviews and book chapters. He has been the recipient of 4 NIH merit awards for his work on retrovirus molecular biology.

He currently serves on advisory committees to the National Cancer Institute and National Institute of Allergy and Infectious Diseases, as well as on the Editorial boards of academic journals, and on the external advisory committees to several academic and commercial institutions.


Robin Shattock

Robin Shattock
Imperial College London, UK


Robin Shattock is a professor of Mucosal Infection and Immunity at Imperial College, London. The main focus of his research is the investigation of the mechanisms of mucosal HIV transmission and development of novel preventative strategies. Prof Shattock has secured funding from the Wellcome Trust, NIH, European Commission, and the Bill and Melinda Gates Foundation. He currently holds a Grand Challenges for Global Health Initiative program grant to optimize vaginal vaccination against HIV infection. He also leads the Mucosal Discovery Team for CHAVI-ID (the Center for HIV AIDS Vaccine Immune Design) funded by NIH. He provides scientific coordination for European Microbicide program CHAARM (Combined Highly Active Anti-Retroviral Microbicides) and MOTIF. Prof. Shattock Chairs the Research and Advisory Steering Committee of the International Partnership for Microbicides and the WHO AIDS Vaccine Advisory committee and is a member of the Scientific Advisory boards of Global HIV Vaccine Enterprise Scientific Committee (GHVE) and the International AIDS Vaccine Initiative.